Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rongliflozin in Chinese Subjects With Type 2 Diabetes With Normal Renal Function and Mild to Moderate Renal Impairment
NCT05374343Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- May 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rongliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Plasma concentrations of rongliflozin. Started May 2022; status: completed.
02
Drugs
rongliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05374343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374343.